Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre …
R Carbonell, S Urgelés, A Rodríguez… - The Lancet Regional …, 2021 - thelancet.com
Background It is unclear whether the changes in critical care throughout the pandemic have
improved the outcomes in coronavirus disease 2019 (COVID-19) patients admitted to the …
improved the outcomes in coronavirus disease 2019 (COVID-19) patients admitted to the …
Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients
JJ Broseta, D Rodríguez-Espinosa, N Rodríguez… - American Journal of …, 2021 - Elsevier
Rationale & Objective Patients with kidney failure who are receiving maintenance dialysis
have a higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS …
have a higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS …
6-month mortality and readmissions of hospitalized COVID-19 patients: A nationwide cohort study of 8,679 patients in Germany
Background COVID-19 frequently necessitates in-patient treatment and in-patient mortality is
high. Less is known about the long-term outcomes in terms of mortality and readmissions …
high. Less is known about the long-term outcomes in terms of mortality and readmissions …
Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
RR Razonable, C Pawlowski, JC O'Horo, LL Arndt… - …, 2021 - thelancet.com
Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …
[HTML][HTML] Bacterial co-infection at hospital admission in patients with COVID-19
E Moreno-García, P Puerta-Alcalde, L Letona… - International Journal of …, 2022 - Elsevier
Objectives We described the current incidence and risk factors of bacterial co-infection in
hospitalized patients with COVID-19. Methods Observational cohort study was performed at …
hospitalized patients with COVID-19. Methods Observational cohort study was performed at …
[HTML][HTML] Клинические особенности постковидного периода. Результаты международного регистра “Анализ динамики коморбидных заболеваний у пациентов …
ГП Арутюнов, ЕИ Тарловская… - Российский …, 2021 - cyberleninka.ru
Цель. Изучение особенностей течения новой коронавирусной инфекции (COVID-19) и
динамики коморбидных состояний у пациентов, перенесших COVID-19, спустя 3, 6, 12 …
динамики коморбидных состояний у пациентов, перенесших COVID-19, спустя 3, 6, 12 …
Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review
M Murton, E Drane, J Jarrett, OA Cornely, A Soriano - Infection, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) pandemic has been a global health
emergency since December 2019, leading to millions of deaths worldwide and placing …
emergency since December 2019, leading to millions of deaths worldwide and placing …
Assessing sex differential in COVID-19 mortality rate by age and polymerase chain reaction test results: an Iranian multi-center study
M Azizmohammad Looha… - Expert review of anti …, 2022 - Taylor & Francis
Background The aim of this study is to evaluate the sex differential effect in the COVID-19
mortality by different age groups and polymerase chain reaction (PCR) test results …
mortality by different age groups and polymerase chain reaction (PCR) test results …
Trends in COVID-19 case-fatality rates in Brazilian public hospitals: A longitudinal cohort of 398,063 hospital admissions from 1st March to 3rd October 2020
IR Zimmermann, MN Sanchez, GS Frio, LC Alves… - PLoS …, 2021 - journals.plos.org
Background Almost 200,000 deaths from COVID-19 were reported in Brazil in 2020. The
case fatality rate of a new infectious disease can vary by different risk factors and over time …
case fatality rate of a new infectious disease can vary by different risk factors and over time …
Association between dexamethasone treatment after hospital discharge for patients with COVID-19 infection and rates of hospital readmission and mortality
CW Huang, SY Albert, H Song, JS Park… - JAMA network …, 2022 - jamanetwork.com
Importance Current guidelines recommend use of dexamethasone, 6 mg/d, up to 10 days or
until discharge for patients hospitalized with COVID-19. Whether patients who received less …
until discharge for patients hospitalized with COVID-19. Whether patients who received less …